---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-100776"
form_type: "8-K"
ticker: "CERT"
cik: "0001827090"
company_name: "Certara, Inc."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:58:03.201122+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Certara acquires Pinnacle 21 for $310M in cash and stock

## Summary
- Enterprise value $310M: $250M cash + $60M in newly issued Certara shares.
- Acquisition expected to be immediately accretive to revenue, revenue growth, and adjusted EBITDA margin.
- Pinnacle 21 provides FDA/PMDA-required clinical data standardization software; 22 of top 25 pharma companies are customers.
- Transaction unanimously approved; expected to close early Q4 2021 subject to regulatory approvals.
- Deal expands Certara's biosimulation platform into data fitness and regulatory software.

## SEC filing metadata
- accession: 0001104659-21-100776
- form_type: 8-K
- ticker: CERT
- cik: 0001827090
- company_name: Certara, Inc.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827090/000110465921100776/0001104659-21-100776-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827090/000110465921100776/tm2123444d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-100776
- JSON: https://secwatch.observer/filing/0001104659-21-100776.json
- Plain text: https://secwatch.observer/filing/0001104659-21-100776.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.